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Abstract
Background: Glutathione S-transferase pi (GST pi) is a subgroup of GST family, which provides cellular protection 
against free radical and carcinogenic compounds due to its detoxifying function. Expression patterns of GST pi have 
been studied in several carcinomas and its down-regulation was implicated to be involved in malignant transformation 
in patients with Barrett's esophagus. However, neither the exact role of GST pi in the pathogenesis nor its prognostic 
impact in squamous esophageal carcinoma is fully characterized.
Methods: Immunohistochemistry was used to investigate GST pi expression on 153 archival squamous esophageal 
carcinoma specimens with a GST pi monoclonal antibody. Statistic analyses were performed to explore its association 
with clinicopathological factors and clinical outcome.
Results: The GST pi expression was greatly reduced in tissues of esophageal carcinomas compared to adjacent normal 
tissues and residual benign tissues. Absent of GST pi protein expression in cytoplasm, nuclear and cytoplasm/nucleus 
was found in 51%, 64.7% and 48% of all the carcinoma cases, respectively. GST pi deficiency in cytoplasm, nucleus and 
cytoplasm/nucleus was significantly correlated to poor differentiation (p < 0.001, p < 0.001 and p < 0.001, respectively). 
UICC stage and T stage were found significantly correlated to negative expression of GST pi in cytoplasm (p < 0.001 and 
p = 0.004, respectively) and cytoplasm/nucleus (p = 0.017 and p = 0.031, respectively). In univariate analysis, absent of 
GST pi protein expression in cytoplasm, nucleus and cytoplasm/nucleus was significantly associated with a shorter 
overall survival (p < 0.001, p < 0.001 and p < 0.001, respectively), whereas only GST pi cytoplasmic staining retained an 
independent prognostic significance (p < 0.001) in multivariate analysis.
Conclusions: Our results show that GST pi expression is down regulated in the squamous esophageal carcinoma, and 
that the lack of GST pi expression is associated with poor prognosis. Therefore, deficiency of GST pi protein expression 
may be an important mechanism involved in the carcinogenesis and progression of the squamous esophageal 
carcinoma, and the underlying mechanisms leading to decreased GST pi expression deserve further investigation.
Background
Esophageal cancer (EC) ranks the third among most
common cancer of the digestive tract and the seventh
leading cause of cancer-related deaths worldwide [1,2].
With new cases accounting for nearly half new cases of
the world per year, China is among the highest incidence
areas [3]. EC is usually diagnosed at late stages with a
five-year survival rate of only 5-10 percent [3,4]. Surgical
resection is believed to offer the best chance for long-
term survival compared to other therapies such as radio-
and chemotherapy, used alone or in combination as adju-
vant treatments [3,5-8]. However, surgical resection is
often unavoidably followed by considerable compromised
life-quality. Therefore, individualized therapy which ben-
efits patients with the highest treatment efficiency yet the
least morbidity is increasing stringent for treatment.
To pave the way for it, it is important to identify prognos-
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tumor [9].
Glutathione S-transferases (GSTs), a supergene family
with at least four distinct isoforms (α, μ, π, θ) identified in
human, are involved in the metabolism of xenobiotic
compounds in the phase II detoxification [10-12]. They
are capable of converting a variety of electrophilic and
hydrophobic compounds into more soluble, more easily
excretable compounds through catalyzing them in con-
junction with glutathione [10]. As numerous potentially
toxic carcinogenic compounds, being electrophilic and
hydrophobic, are detoxified in this way, GSTs is believed
to play an important role in cancer prevention [13,14].
Down-regulation of GSTs has been reported as an
increased risk for developing gastric, colorectal, and lung
cancer [15-17]. Decreased GST enzyme activity in the
gastrointestinal track is implicated with a raised tumor
incidence [2].
GST pi, the predominant isoform in the normal
squamous esophagus epithelium [18], is present in a wide
range of normal human tissues [18,19], as well as in vari-
ous malignant tumors of urinary, digestive, and respira-
tory tracts [20-24]. No consensus has been achieved yet
regarding to the association between GST pi expression
and malignant transformation. Some studies suggest an
increased expression of GST pi as an indicator for prema-
lignant and malignant changes [25,26]; Whereas, in oth-
ers, GST pi expression is indicated to be a marker of
carcinogen exposure in the upper aerodigestive tract [27-
30]. Meanwhile, in some studies, loss of GST pi expres-
sion is suggested as a phenotype associated with carcino-
genesis [31,32].
As to the alternation of GST pi in development of
esophageal carcinoma, several studies have been per-
formed on Barrett's metaplasia and adenocarcinoma with
results suggesting deficiency of GST pi may contribute to
an increased cancer risk [2,33,34]. However, limited
knowledge is available in terms of GST pi alternation in
squamous esophageal carcinoma, as well as its connec-
tion with clinical parameters. Therefore, in the present
study, we report results of an immunohistochemical sur-
vey of GST pi in 153 squamous esophageal carcinoma
cases with a long term follow-up. Our study confirms a
down-regulated GST pi expression in this type of tumor,
and demonstrates the deficiency of GST pi protein
expression is significantly associated with a shorter over-
all survival.
Methods
Patient materials
One hundred and fifty-three patients composed by 93
men and 60 women with esophageal squamous cell carci-
noma, whom underwent potentially curative surgery dur-
ing 1989-1994 at Anyang Tumor Hospital, Henan, China,
were enrolled in this retrospective study. The median age
at diagnosis was 56.4 years (range 33-73 years). No preop-
erative chemotherapy and radiotherapy were given. All
tumors were staged according to International Union
against Cancer (UICC) 2003 Classification. One hundred
(65.4%) cases were classified as stage II and 53 (34.6%)
cases as III. All patients were followed up until death or
31. May, 2004. Ninety-seven (63.4%) patients died of
esophageal cancer. The median follow-up time for all
patients was 90 months (range 1-155 months). The fol-
low-up and data analyses were performed by researchers
from both sides of this international cooperation project,
Anyang Tumor Hospital, China and The Norwegian
Radium Hospital, Norway. Patients' information included
tumor size, TNM staging, pathologic grade, demographic
data and mortality. Study approval was given by the
Regional Committee for Medical Research Ethics in Nor-
way.
Specimens removed from surgery were fixed in forma-
lin, processed and embedded in paraffin blocks for diag-
nosis and research use. Histological specimens were
reviewed by two of the co-authors (Z.S and J.M.N) who
had no access to clinical information. The detailed
description as to the tumor characteristics was listed in
Table 1.
Tissue array method
Multi-tissue array paraffin blocks were produced by a
MTA-1 manual tissue arrayer (Beecher Instruments Inc.,
Sun Prairie, WI, U.S.A), before 5 μm paraffin sections
were cut and underwent the Hematoxyline and Eosin
(H&E) staining. After evaluation, two representative
tumor areas and one stroma area on each sample were
selected, respectively. The chosen regions were then
removed from the original paraffin block to a recipient
paraffin block by using the hollow-cored needles with the
core-diameter of 0.6 mm. By this way, the pin-picked
chosen tissues were arrayed on the recipient paraffin
block. Finally, five μm sections made from those recipient
paraffin blocks were cut and mounted on the charged
Super-Frost Plus glass slides, and ready for immunohis-
tochemistry analysis after pre-dried at 60ÂºC in an oven
for 2-4 hours. For samples on which the representative
areas were failed to choose for tissue array, five μm sec-
tions from the whole tissue paraffin blocks underwent
immunohistochemical analysis as well.
Immunohistochemical method
Dako EnVision™ + System, Peroxidase (DAB) (K4007,
Dako Corporation, CA, and U.S.A) was employed for
immunostaining. Sections were first deparaffinized in
xylene and microwaved in 10 mM citrate buffer pH 6.0 to
unmask the epitopes, and then treated with 0.3% hydro-
gen peroxide (H2O2) for 5 min to block the endogenous
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feranse pi antibody (clone 353-10, 1:50, from Acris Anti-
bodies GmbH, Germany) was applied on the sections for
30 min at room temperature, followed by an incubation
with the horzeradish peroxidase (HRP) labeled polymer
conjugated to goat anti-mouse IgG for 30 min at room
temperature. Sections were then incubated with 3'3-
diaminobenzidine tetrahydrochloride (DAB) for 10 min,
and counterstained with hematoxylin, dehydrated and
mounted in Diatex before evaluation.
Immunostaining of each section was semiquantitatively
scored for both intensity (1, absent/weak; 2, moderate; 3,
strong) and extent of staining (percentage of the positive
tumor cells: 1, < 10%; 2, 10-50%; 3, > 50%). The scoring
results of intensity and extent were multiplied to give a
composite score ranging from 1 to 9 for each section.
Table 1: GST pi immunostaining in relation to clinicopathological variables
Variables Total Cytoplasm Nucleus Cytoplasm and Nucleus
N (%) Negative
(%)
Positive p1 Negative
(%)
Positive p1 Negative
(%)
Positive p1
Age 0.019 0.405 0.060
<51 48 (31) 18 (38) 30 28 (58) 20 19 (40) 29
51-60 52 (34) 34 (65) 18 37 (71) 15 32 (62) 20
>60 53 (35) 26 (49) 27 34 (64) 19 23 (43) 30
gender 0.185 0.302 0.136
Male 93 (61) 43 (46) 50 57 (61) 36 40 (43) 53
Female 60 (39) 35 (58) 25 42 (70) 18 34 (57) 26
Histological grade <0.001 <0.001 <0.001
Well 53 (35) 13 (25) 40 22 (42) 31 12 (23) 41
Moderate 60 (39) 38 (63) 22 45 (75) 15 36 (60) 24
Poor 40 (26) 27 (68) 13 32 (80) 8 26 (65) 14
Location 0.232 0.929 0.995
Upper 14 (9) 5 (36) 9 9 (64) 5 7 (50) 7
Middle 101 (66) 47 (47) 54 67 (66) 34 49 (49) 52
Lower 35 (23) 21 (60) 14 22 (63) 13 17 (49) 18
Missing 3 (2) 2 1 2 1 2 1
Size 0.238 0.973 0.843
≤30 mm 25 (16) 11 (44) 14 17 (68) 8 11 (44) 14
31-60 mm 105 (69) 59 (56) 46 70 (67) 35 53 (51) 52
>60 mm 14 (9) 5 (36) 9 9 (64) 5 7 (50) 7
Missing 9 (6) 3 6 4 5 3 6
Lymph node metastasis 0.090 0.727 0.398
- 99 (65) 45 (46) 54 63 (64) 36 45 (46) 54
+ 54 (35) 33 (61) 21 36 (67) 18 29 (54) 25
UICC stage <0.001 0.377 0.017
II 100 (65) 40 (40) 60 62 (62) 38 41 (41) 59
III 53 (35) 38 (71) 15 37 (70) 16 33 (62) 20
T stage 0.004 0.126 0.031
I+II 44 (29) 14 (32) 30 23 (52) 21 14 (32) 30
III 100 (65) 57 (57) 43 70 (70) 30 54 (54) 46
IV 9 (6) 7 (78) 2 6 (67) 3 3 (33) 6
1Pearson chi-square
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independent observers (Z.W and Z.S) with no knowledge
of patients outcome. All discordant scores were reviewed
until final agreements were obtained.
Statistical analyses
The associations between GST pi protein expression and
clinicopathologic variables were evaluated by the Person
χ2 test. The Kaplan - Meier method were employed to
estimate the survival rate. A Cox proportional hazards
regression model was formed to perform multivariate
evaluation of survival rates, after the fulfillment of pro-
portional hazard assumption of variables was evaluated
by STATA statistical software package (Stata 10.0, collage
station, TX). The calculation was performed by usage of
the SPSS 16.0 statistical software package (SPSS, Chicago,
IL), and p â‰¤ 0.05 was considered as statistical signifi-
cance.
Results
Frequency of GST pi protein expression
The majority of cases contained adjacent normal tissues
and residual benign tissues, on which strong positive
staining presented and served as the internal control for
both cytoplasm and nucleus. Immunostaining in adjacent
normal tissues and residual benign tissues was found in
parabasal, middle and top layers of the esophageal epithe-
lium (Figure 1a and 1b).
In esophageal carcinomas, positive immunostaining in
either cytoplasm (Figure 1c), or nucleus (Figure 1d), or
cytoplasm/nucleus (Figure 1e) was discoved in 75 (49%),
54 (35.3%), and 79 (51.6%) cases, respectively. Negative
immunostaining for GST pi in either cytoplasam (Figure
1d), or nucleus (Figure 1c), or both cytoplasma and
nucleus (Figure 1f) was found in 78 (51%), 99 (64.7%), and
74 (48.4%) cases, respectively. The summarized GST pi
immunostaining score was listed in Table 2.
GST pi immunostaining in relation to clinicopathological 
parameters and patients survival
GST pi immunostaining status in relation to clinico-
pathological parameters was summarized in Table1. Neg-
ative expression of GST pi in cytoplasm, nucleus and
cytoplasm/nucleus was significantly correlated to high
histological grade (p < 0.001, p < 0.001 and p < 0.001,
respectively). UICC stage and T stage were found signifi-
cantly correlated to negative expression of GST pi in
cytoplasm (p < 0.001 and p = 0.004, respectively) and
cytoplasm/nucleus (p = 0.017 and p = 0.031, respectively).
No significant associations were found between GST pi
expression levels and age, gender, location, tumor size
and lymph node metastasis.
In evalution of proportional hazard assumption of vari-
ables, it was found that variables including UICC stage, T
stage and GST pi staining in cytoplasm, nucleus and
cytoplasm/nucleus were qualified for such analysis, and
all survival curves did not cross substantially. Histological
grade did not fulfill proportional hazard assumption, but
was used in multivariate analysis as a strata variate. In
univariate analysis, high UICC stage (p < 0.001), high T
stage (p < 0.001 and p = 0.001), and GST pi staining in
cytoplasm, nucleus and cytoplasm/nucleus (p < 0.001, p <
0.001 and p < 0.001 respectively) were associated with
poor overall survival (Figure 2). In multivariate analysis
with histological grade as a strata variate, only T stage
and GST pi cytoplasmic staining retained independent
prognostic significance (p < 0.001, p < 0.001 and p <
0.001, respectively) (Table 3).
Discussion
Previously, GST pi expression in tissue and serum was
suggested as a cancer marker in several studies [10,26],
with results showing inconsistent GST pi expression pat-
terns in various carcinomas. In gastric cancer, an
increased serum GST pi was hypothesized to correlate to
the advanced stage, and its expression in tissue was found
inversely correlated to survival [35]. In precancerous foci
of colorectal polyps, an increased GST pi expression pre-
sented in the high grade adenoma [36]. However, in pros-
tate adenocarcinoma, down-regulation of GST pi was
observed and the loss of GST pi expression was regarded
as a phenotype associated with malignant transformation
[31,37].
In esophageal carcinomas, many studies showed that
down-regulation of GST pi expression was involved in
malignant progression from Barrett's esophagus to
esophageal adenocarcinoma [2,34]. The decreased GST
pi expression was observed in Barrett's epithelium
[2,34,38], and lower GST pi mRNA levels were detected
by Northern blot analysis and measurements of enzy-
matic activity [38-40]. These studies anticipated that the
absence of this detoxifying enzyme may play an impor-
tant role in development and progression of esophageal
carcinoma [38,41]. However, a study on limited samples
(53 samples from 19 patients) by Chandra et al. [2] argued
that high GST pi expression connoted a poor prognosis.
At the same time, the authors failed in finding statistical
significant difference to the disease-free survival [2].
In our present study, down-regulated GST pi was
observed in squamous esophageal carcinomas, a finding
which is rather consistent with the esophageal carcinoma
studies by Huang et al. [42] and Fu et al. [43]. Both
Huang's and our study find that loss of GST pi expression
is associated with clinicopathological factor of high histo-
logical grade. Furthermore, our results also demonstrate
that the reduced GST pi expression is correlated to the
overall survival, indicating that GST pi down-regulation
is not only associated with esophageal tumorigenesis, a
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tions [34,38,44], but also with esophageal tumor progres-
sion.
GST pi polymorphism has been suggested to be
involved in alternation of GST pi enzyme activity. Van et
al. [45] showed that the reduced GST pi enzyme activity
in Barrett's esophagus was attribute to the expression of
GST pi b, a genotype encoding GST pi enzyme with a less
activity, compared with GST pi a. Compton and cowork-
ers [40] suggested that down-regulation of GST pi was
second to the decreased GST pi mRNA level, which hap-
pened in transcription step due to gene interactions [38].
In addition, decreased level of GST pi was implied to con-
nect with the epigenetic alternation, resulting in the tran-
scriptional silence. Hypermethylation of CpG islands
within promoter regions has been found in several genes,
and has been implied to be responsible for down-regula-
tion of their protein products [46-48]. Hypermethylation
of GST pi gene, although happened at a low frequency,
has been reported in esophageal adenocarcinomas [44].
Potential mechanisms accounting for down-regulation of
GST pi in malignant transduction in Barrett's esophagus
may take place in squamous esophageal carcinoma as
well. We speculate that epigenetic alterations may happen
in squamous esophageal carcinomas and results in a
decreased GST pi expression in this type of tumor.
Figure 1 Expression of GST pi protein in squmous esophagus epithelium. Expression of GST pi protein in normal squamous esophagus epithe-
lium (A) and (B). Expression of GST pi protein in esophageal squamous carcinoma with positive immunostaining in cytoplasm and negative in nucleus 
(C). Expression of GST pi protein in esophageal squamous carcinoma with negative immunostaining in cytoplasm and positive in nucleus (D). Expres-
sion of GST pi protein in esophageal squamous carcinoma with positive immunostaining in both cytoplasm and nucleus (E). Expression of GST pi pro-
tein in esophageal squamous carcinomas with negative immunostaining in both cytoplasm and nucleus (F). Original magnification: × 400 (A, B); × 
600 (C-F); × 200 (pictures at lower right corner of C-F).
Table 2: Immunostaining results for GST pi
Score Cytoplasm Nucleus Cytoplasm/nucleus
n (%) n (%) n (%)
0 78 (51.0) 99 (64.7) 74 (48.4)
3 54 (35.3) 43 (28.1) 58 (37.9)
6 21 (13.7) 10 (6.5) 17 (11.1)
9 0 (0) 1 (0.7) 4 (2.6)
Total 153 (100.0) 153 (100.0) 153 (100.0)
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of cancer development is secondary to GST pi down-reg-
ulation or not, but some studies on esophagus have sug-
gested that imbalance between redox and GST enzyme
might get involved [2]. According to the study of Chandra
et al. [2], redox molecular species may play double-edged
roles. On one side, they could kill tumor cells by inducing
cell apoptosis and/or through other mechanisms. On the
other side, due to the redox-mediated damages on DNA
molecules, they could initiate a cascade of mutational
events which promoted the development or progression
of malignancy.
Studies on NOâˆ™, a redox molecular, have found that
upper aerodigestive track malignancies strongly
expressed the enzymatic machinery necessary to generate
NOâˆ™, in spite of its known physiologic roles on regula-
tion of vascular blood flow and an assistance on killing
infectious and malignant cells [49,50]. The prevalence
expression of NOâˆ™ in tumor cells indicated a potential
high concentration of NOâˆ™ in microenvironment of
tumor [1,33,51] raising concerns of mutagenesis due to
breaking up the double-strand structure of DNA mole-
cules [52]. However, effects of high NOâˆ™ levels can be
counteracted by glutathione [53]. GST enzymes, by cata-
lyzing glutathione to nucleophilic compounds, provide a
key biochemical sink for free radicals and highly reactive
molecules [2]. Lack of GST expression may lead to accu-
mulation of redox-mediated DNA damages in cells, con-
tributing to genome instability as a result of an imbalance
between GST enzymes and redox species.
As to development and progression of squamous
esophageal carcinoma, we speculate that lack or loss of
GST pi protein expression may predispose a normal cell
to undergo further genetic alternations, raising risks of
malignant changes ultimately and even tumor progres-
sion.
Conclusions
The present study, by using immunohistochemistry on
153 cases, confirms that the expression of GST pi is
down-regulated in squamous esophageal epithermal car-
cinomas and significantly associated with poor overall
survival. Deficiency of GST pi protein expression may be
an important mechanism involved in the carcinogenesis
Table 3: Relative risk (RR) of dying from esophageal squamous carcinoma
Variables Univariate analysis Multivariate analysis
RR 95% CIa p RR 95% CIa p
UICC stage 3.37 2.24-5.07 <0.001 - - -
T stage (III/I+ II) 3.46 1.86-6.44 <0.001 3.94 2.22-7.01 <0.001
T stage (IV/I + II) 4.85 1.98-11.91 0.001 8.83 3.73-20.90 <0.001
GSTpi cytoplasmic staining 5.63 3.50-9.06 <0.001 4.80 2.94-7.84 <0.001
GSTpi nucleus staining 2.92 1.80-4.73 <0.001 - - -
GSTpi cytoplasmic/nucleus staining 3.95 2.56-6.11 <0.001 - - -
a95% confidence interval
Figure 2 Survival curves using the Kaplan-Meier method. Kaplan-Meier curves drawn for the entire series (n = 153) based on GST pi protein ex-
pression levels in cytoplasm (p = 0.001) (A). Kaplan-Meier curves drawn for the entire series (n = 153) based on GST pi protein expression levels in nu-
cleus (p < 0.001) (B). Kaplan-Meier curves drawn for the entire series (n = 153) based on GST pi protein expression levels in cytoplasm/nucleus (p = 
0.001) (C).
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Further studies are deserved to explore the underlying
mechanisms leading to decreased GST pi expression in
this type of tumor.
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